Literature DB >> 11796270

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.

Carsten Stephan1, Klaus Jung, Eleftherios P Diamandis, Harry G Rittenhouse, Michael Lein, Stefan A Loening.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11796270     DOI： 10.1016/s0090-4295(01)01449-2

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


× No keyword cloud information.
  13 in total

1.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer.

Authors:  Shahrokh F Shariat; Eduardo I Canto; Michael W Kattan; Kevin M Slawin
Journal:  Rev Urol       Date:  2004

2.  Prostate-specific antigen kallikrein and the heart.

Authors:  Salvatore Patanè
Journal:  World J Cardiol       Date:  2009-12-31

3.  New serum biomarkers for prostate cancer diagnosis.

Authors:  Kailash C Chadha; Austin Miller; Bindukumar B Nair; Stanley A Schwartz; Donald L Trump; Willie Underwood
Journal:  Clin Cancer Investig J       Date:  2014

4.  Expression patterns of murine antichymotrypsin-like genes reflect evolutionary divergence at the Serpina3 locus.

Authors:  Anita J Horvath; Sharon L Forsyth; Paul B Coughlin
Journal:  J Mol Evol       Date:  2004-10       Impact factor: 2.395

5.  Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.

Authors:  Jeremy G Stone; Raj K Rolston; Masumi Ueda; Hyoung-Gon Lee; Sandy L Richardson; Rudy J Castellani; George Perry; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-10-20

6.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

Review 7.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

8.  [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l].

Authors:  C Stephan; B Vogel; H Cammann; M Lein; V Klevecka; P Sinha; G Kristiansen; D Schnorr; K Jung; S A Loening
Journal:  Urologe A       Date:  2003-03-22       Impact factor: 0.639

Review 9.  Emerging PSA-based tests to improve screening.

Authors:  Richard J Bryant; Hans Lilja
Journal:  Urol Clin North Am       Date:  2014-02-26       Impact factor: 2.241

10.  Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.

Authors:  K Oikonomopoulou; L Li; Y Zheng; I Simon; R L Wolfert; D Valik; M Nekulova; M Simickova; T Frgala; E P Diamandis
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.